Advertisement

Prospective Role of Glycosaminoglycans in Apoptosis Associated with Neurodegenerative Disorders

  • Bertalan Dudas
  • Amira Lemes
  • Umberto Cornelli
  • Israel Hanin
Conference paper
Part of the Advances in Behavioral Biology book series (ABBI, volume 57)

Keywords

Nerve Growth Factor Lateral Septum Neurobiol Aging Fiber Varicosity Lateral Septal Nucleus 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Engidawork E, Gulesserian T, Seidl R, et al. Expression of apoptosis related proteins in brains of patients with Alzheimer's disease. Neurosci Lett 2001;303:79–82.PubMedCrossRefGoogle Scholar
  2. 2.
    Engidawork E, Gulesserian T, Yoo BC, et al. Alteration of caspases and apoptosis-related proteins in brains of patients with Alzheimer's disease. Biochem Biophys Res Commun 2001;281:84–93.PubMedCrossRefGoogle Scholar
  3. 3.
    Rideout HJ, Stefanis L. Caspase inhibition: a potential therapeutic strategy in neurological diseases. Histol Histopathol 2001;16:895–908.PubMedGoogle Scholar
  4. 4.
    Sigurdsson EM, Lorens SA, Hejna MJ, et al. Local and distant histopathological effects of unilateral amyloid-beta 25-35 injections into the amygdala of young F344 rats. Neurobiol Aging 1996;17:893–901.PubMedCrossRefGoogle Scholar
  5. 5.
    Dudas B, Cornelli U, Lee JM, et al. Oral and subcutaneous administration of the glycosaminoglycan C3 attenuates Aβ (25-35)-induced abnormal tau protein immunoreactivity in rat brain. Neurobiol Aging 2002;23:97–104.PubMedCrossRefGoogle Scholar
  6. 6.
    Rose M, Dudas B, Cornelli U, Hanin I. Protective effect of the heparin-derived oligosaccharide C3, on AF64A-induced cholinergic lesion in rats. Neurobiol Aging 2003;24:481–490.PubMedCrossRefGoogle Scholar
  7. 7.
    Kisilevsky R, Lemieux LJ, Fraser PE, et al. Arresting amyloidosis in vivo using small-molecule anionic sulphonates or sulphates: implications for Alzheimer's disease. Nat Med 1995;1:143–148.PubMedCrossRefGoogle Scholar
  8. 8.
    Mervis RF, McKean J, Zats S, et al. Neurotrophic effects of the glycosaminoglycan C3 on dendritic arborization and spines in the adult rat hippocampus: a quantitative golgi study. CNS Drug Reviews 2000;44–46.Google Scholar
  9. 9.
    Damon DH, D'Amore PA, Wagner JA. Sulfated glycosaminoglycans modify growth factor-induced neurite outgrowth in PC12 cells. J Cell Physiol 1988;135:293–300.PubMedCrossRefGoogle Scholar
  10. 10.
    Lesma E, Di Giulio AM, Ferro L, et al. Glycosaminoglycans in nerve injury. 1. Low doses of glycosaminoglycans promote neurite formation. J Neurosci Res 1996;46:565–571.PubMedCrossRefGoogle Scholar
  11. 11.
    Dudas B, Rose M, Cornelli U, Hanin I. Low molecular weight glycosaminoglycan C3 attenuates AF64A-stimulated, low-affinity nerve growth factor receptor-immunoreactive axonal varicosities in the rat septum. Brain Res 2005;1033:34–40.PubMedCrossRefGoogle Scholar
  12. 12.
    Bose P, Black S, Kadyrov M, et al. Heparin and aspirin attenuate placental apoptosis in vitro: implications for early pregnancy failure. Am J Obstet Gynecol 2005;192:23–30.PubMedCrossRefGoogle Scholar
  13. 13.
    Vincent T, Molina L, Espert L, Mechti N. Hyaluronan, a major non-protein glycosaminoglycan component of the extracellular matrix in human bone marrow, mediates dexamethasone resistance in multiple myeloma. Br J Haematol 2003;121:259–269.PubMedCrossRefGoogle Scholar
  14. 14.
    Cartel NJ, Post M. Abrogation of apoptosis through PDGF-BB-induced sulfated glycosaminoglycan synthesis and secretion. Am J Physiol Lung Cell Mol Physiol 2005;288:L285–L293.Google Scholar
  15. 15.
    Ma Q, Dudas B, Hejna M, et al. The blood-brain barrier accessibility of a heparin-derived oligosaccharide, C3. Thromb Res 2002;105:447–453.PubMedCrossRefGoogle Scholar
  16. 16.
    Fisher A, Hanin I. Potential animal models for senile dementia of Alzheimer's type, with emphasis on AF64A-induced cholinotoxicity. Annu Rev Pharmacol Toxicol 1986;26:161–181.PubMedCrossRefGoogle Scholar
  17. 17.
    Rose M, Dudas B, Cornelli U, Hanin I. Glycosaminoglycan C3 protects against AF64A-induced cholinotoxicity in a dose-dependent and time-dependent manner. Brain Res 2004;1015:96–102.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Bertalan Dudas
    • 1
  • Amira Lemes
  • Umberto Cornelli
  • Israel Hanin
  1. 1.Neuroendocrine Organization Laboratory (NEO), Lake Erie College of Osteopathic MedicineErieUSA

Personalised recommendations